Abstract
Cnidarians comprise four classes of toxic marine animals: Anthozoa, Cubozoa, Scyphozoa and Hydrozoa. They are the largest and probably the oldest phylum of toxic marine animals. Any contact with a cnidarian, especially the box jellyfish (Chironex fleckeri), can be fatal, but most cnidarians do not possess sufficiently strong venomous apparatus to penetrate the human skin, whereas others rarely come into contact with human beings. Only a small, almost negligible percentage of the vast wealth of cnidarian toxins has been studied in detail. Many polypeptide cnidarian toxins are immunogenic, and cross-reactivity between several jellyfish venoms has been reported. Cnidarians also possess components of innate immunity, and some of those components have been preserved in evolution. On the other hand, cnidarian toxins have already been used for the design of immunotoxins to treat cancer, whereas other cnidarian toxins can modulate the immune system in mammals, including man. This review will focus on a short overview of cnidarian toxins, on the innate immunity of cnidarians, and on the mode of action of cnidarian toxins which can modulate the immune system in mammals. Emphasis is palced on those toxins which block voltage activated potassium channels in the cells of the immune system
Keywords: Cnidaria, coral, hydra, immunosupressant, immunotoxin, jelly fish, octocorals, terpenoids, Chironex fleckeri, potassium channels
Inflammation & Allergy - Drug Targets (Discontinued)
Title: Interactions of Cnidarian Toxins with the Immune System
Volume: 10 Issue: 5
Author(s): Dusan Suput
Affiliation:
Keywords: Cnidaria, coral, hydra, immunosupressant, immunotoxin, jelly fish, octocorals, terpenoids, Chironex fleckeri, potassium channels
Abstract: Cnidarians comprise four classes of toxic marine animals: Anthozoa, Cubozoa, Scyphozoa and Hydrozoa. They are the largest and probably the oldest phylum of toxic marine animals. Any contact with a cnidarian, especially the box jellyfish (Chironex fleckeri), can be fatal, but most cnidarians do not possess sufficiently strong venomous apparatus to penetrate the human skin, whereas others rarely come into contact with human beings. Only a small, almost negligible percentage of the vast wealth of cnidarian toxins has been studied in detail. Many polypeptide cnidarian toxins are immunogenic, and cross-reactivity between several jellyfish venoms has been reported. Cnidarians also possess components of innate immunity, and some of those components have been preserved in evolution. On the other hand, cnidarian toxins have already been used for the design of immunotoxins to treat cancer, whereas other cnidarian toxins can modulate the immune system in mammals, including man. This review will focus on a short overview of cnidarian toxins, on the innate immunity of cnidarians, and on the mode of action of cnidarian toxins which can modulate the immune system in mammals. Emphasis is palced on those toxins which block voltage activated potassium channels in the cells of the immune system
Export Options
About this article
Cite this article as:
Suput Dusan, Interactions of Cnidarian Toxins with the Immune System, Inflammation & Allergy - Drug Targets (Discontinued) 2011; 10 (5) . https://dx.doi.org/10.2174/187152811797200678
DOI https://dx.doi.org/10.2174/187152811797200678 |
Print ISSN 1871-5281 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4055 |
Related Articles
-
Ring Finger Ubiquitin Protein Ligases and Their Implication to the Pathogenesis of Human Diseases
Current Pharmaceutical Design A Common Biological Mechanism in Cancer and Alzheimers Disease?
Current Alzheimer Research Therapy Based on the Regulation of Thiol-dependent Redox Systems
Current Medicinal Chemistry Current Insights into the Role of HIF-1 in Cutaneous Wound Healing
Current Molecular Medicine Emergence of Ad-Mediated Combination Therapy Against Cancer: What to Expect?
Current Cancer Drug Targets Non-Coding RNA in Brain Development and Disorder
Current Medicinal Chemistry Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies
Current Pharmaceutical Design Evasion of Ribonuclease Inhibitor as a Determinant of Ribonuclease Cytotoxicity
Current Pharmaceutical Biotechnology In Vitro High Throughput Phage Display Selection of Ovarian Cancer Avid Phage Clones for Near-Infrared Optical Imaging
Combinatorial Chemistry & High Throughput Screening Entropy and Enthalpy in the Activity of Tubulin-Based Antimitotic Agents
Current Chemical Biology Impaired Autophagy Mediates Resistance to Low-Dose Metronomic Cyclophosphamide Chemotherapy
Clinical Cancer Drugs Development of Novel, Highly Cytotoxic Fusion Constructs Containing Granzyme B: Unique Mechanisms and Functions
Current Pharmaceutical Design Therapeutic Targeting of Apoptotic Pathways: Novel Aspects in Pancreatic Cancer
Current Pharmaceutical Biotechnology Meet the Editorial Board
Current Bioinformatics Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma
Current Pharmaceutical Design Ex Vivo Liver – Directed Gene Therapy for the Treatment of Metabolic Diseases: Advances in Hepatocyte Transplantation and Retroviral Vectors
Current Gene Therapy Recent Advances of Poly(ether-ether) and Poly(ether-ester) Block Copolymers in Biomedical Applications
Current Drug Metabolism Effects of Anesthetics on Mitochondrial Signaling and Function
Current Drug Safety Fluorescein Fluorescence Use in the Management of Intracranial Neoplastic and Vascular Lesions: A Review and Report of a New Technique
Current Drug Discovery Technologies An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Design